WallStreetZenWallStreetZen

NASDAQ: URGN
Urogen Pharma Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for URGN

Based on 3 analysts offering 12 month price targets for Urogen Pharma Ltd

Min Forecast
$33.00+5.33%
Avg Forecast
$39.33+25.54%
Max Forecast
$45.00+43.63%

Should I buy or sell URGN stock?

Based on 3 analysts offering ratings for Urogen Pharma Ltd.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although URGN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates URGN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their URGN stock forecasts and price targets.

URGN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-11
lockedlocked$00.00+00.00%2026-05-07
lockedlocked$00.00+00.00%2026-03-31

1 of 1

Forecast return on equity

Is URGN forecast to generate an efficient return?

Company
-195.11%
Industry
73.87%
Market
169.19%
URGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is URGN forecast to generate an efficient return on assets?

Company
95.56%
Industry
28.49%
URGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

URGN earnings per share forecast

What is URGN's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$1.11
Avg 2 year Forecast
$1.36
Avg 3 year Forecast
$2.75

URGN revenue forecast

What is URGN's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$251.2M+78.81%
Avg 2 year Forecast
$423.9M+201.74%
Avg 3 year Forecast
$529.7M+277.03%
URGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

URGN revenue growth forecast

How is URGN forecast to perform vs Biotechnology companies and vs the US market?

Company
56.94%
Industry
33.6%
Market
14.06%
URGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
URGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

URGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
URGN$31.33$39.33+25.54%Strong Buy
BCAX$22.92$28.67+25.07%Buy
IMTX$11.54$21.25+84.14%Strong Buy
NVAX$9.50$13.67+43.86%Hold
PGEN$4.20$9.50+126.19%Buy
View Top Biotech Stocks

Urogen Pharma Stock Forecast FAQ

Is Urogen Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: URGN) stock is to Strong Buy URGN stock.

Out of 3 analysts, 1 (33.33%) are recommending URGN as a Strong Buy, 2 (66.67%) are recommending URGN as a Buy, 0 (0%) are recommending URGN as a Hold, 0 (0%) are recommending URGN as a Sell, and 0 (0%) are recommending URGN as a Strong Sell.

If you're new to stock investing, here's how to buy Urogen Pharma stock.

What is URGN's earnings growth forecast for 2026-2028?

(NASDAQ: URGN) Urogen Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.12%.

Urogen Pharma's earnings in 2026 is -$133,225,000.On average, 10 Wall Street analysts forecast URGN's earnings for 2026 to be -$54,042,111, with the lowest URGN earnings forecast at -$95,017,061, and the highest URGN earnings forecast at -$10,231,557. On average, 10 Wall Street analysts forecast URGN's earnings for 2027 to be $66,310,235, with the lowest URGN earnings forecast at $21,486,270, and the highest URGN earnings forecast at $158,589,137.

In 2028, URGN is forecast to generate $133,931,084 in earnings, with the lowest earnings forecast at $57,296,720 and the highest earnings forecast at $169,843,850.

What is URGN's revenue growth forecast for 2026-2028?

(NASDAQ: URGN) Urogen Pharma's forecast annual revenue growth rate of 56.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.

Urogen Pharma's revenue in 2026 is $140,493,000.On average, 10 Wall Street analysts forecast URGN's revenue for 2026 to be $12,239,378,508, with the lowest URGN revenue forecast at $10,470,780,762, and the highest URGN revenue forecast at $13,863,760,020. On average, 10 Wall Street analysts forecast URGN's revenue for 2027 to be $20,654,103,488, with the lowest URGN revenue forecast at $15,746,853,763, and the highest URGN revenue forecast at $29,292,948,292.

In 2028, URGN is forecast to generate $25,807,885,020 in revenue, with the lowest revenue forecast at $21,204,658,709 and the highest revenue forecast at $30,564,097,471.

What is URGN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: URGN) forecast ROA is 95.56%, which is higher than the forecast US Biotechnology industry average of 28.49%.

What is URGN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year URGN price target, the average URGN price target is $39.33, with the highest URGN stock price forecast at $45.00 and the lowest URGN stock price forecast at $33.00.

On average, Wall Street analysts predict that Urogen Pharma's share price could reach $39.33 by May 11, 2027. The average Urogen Pharma stock price prediction forecasts a potential upside of 25.54% from the current URGN share price of $31.33.

What is URGN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: URGN) Urogen Pharma's current Earnings Per Share (EPS) is -$2.74. On average, analysts forecast that URGN's EPS will be -$1.11 for 2026, with the lowest EPS forecast at -$1.95, and the highest EPS forecast at -$0.21. On average, analysts forecast that URGN's EPS will be $1.36 for 2027, with the lowest EPS forecast at $0.44, and the highest EPS forecast at $3.26. In 2028, URGN's EPS is forecast to hit $2.75 (min: $1.18, max: $3.49).

What is URGN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: URGN) forecast ROE is -195.11%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.